Allergan, Pfizer Deal Goes Through with Allergan Bigger Than Pfizer: But at What Cost to R&D? Curator: Stephen J. Williams, Ph.D. Just recently this site had a post entitled Pfizer Near Allergan Buyout Deal But Will Fed Allow It? Now, as Bloomberg reports the international deal between Allergan and Pfizer has gone through, resulting in a […]
Search Results for 'Allergan'
Allergan, Pfizer Deal Goes Through with Allergan Bigger Than Pfizer: But at What Cost to R&D?
Posted in Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, tagged #biotech, #pharmanews, Allergan, Biomedical Research Workforce, Mergers and acquisitions, Pfizer, R&D on November 23, 2015| Leave a Comment »
Pfizer Near Allergan Buyout Deal But Will Fed Allow It?
Posted in Pharmaceutical Industry Competitive Intelligence, tagged #pharmanews, Food and Drug Administration, IRS, Mergers and acquisitions on November 19, 2015| Leave a Comment »
Pfizer Near Allergan Buyout Deal But Will Fed Allow It? Reporter: Stephen J. Williams, Ph.D. From Bloomberg Business™ Pfizer Inc. is in advanced talks to buy Allergan Plc for as much as $380 per share, according to people familiar with the matter, valuing the Botox maker at as high as $150 billion — […]
M&A – New Rules in the Game: @Tulane University’s Law School, M&A Conference – Allergan Inc.’s $66 billion sale to Actavis PLC
Posted in Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment on March 30, 2015| Leave a Comment »
M&A – New Rules in the Game: @Tulane University’s Law School, M&A Conference – Allergan Inc.’s $66 billion sale to Actavis PLC Reporter: Aviva Lev-Ari, PhD, RN The deal, Allergan Inc.’s $66 billion sale to Actavis PLC, closed on 3/22/2015, ahead of schedule and 11 months after Valeant Pharmaceuticals International Inc. and activist William Ackman’s hedge-fund firm had […]
Allergan agrees to $66 billion Actavis offer $219 a share
Posted in Pharmaceutical Industry Competitive Intelligence on November 17, 2014| Leave a Comment »
Allergan agrees to $66 billion Actavis offer $219 a share Reporter: Aviva Lev-Ari, PhD, RN (Reuters) – Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc. Dublin-based Actavis offered $219 per share in cash and stock, amounting […]
Top 15 pharmas, then=2026 and now=2020: How the next five years will shake up Big Pharma’s rankings
Posted in Pharmaceutical Analytics, Pharmaceutical Industry Competitive Intelligence on July 14, 2020| Leave a Comment »
Top 15 pharmas, then=2026 and now=2020: How the next five years will shake up Big Pharma’s rankings Reporter: Aviva Lev-Ari, PhD, RN As the pharma industry enters a new decade, the world’s largest drug companies are busy launching new meds, restructuring to focus on innovative offerings and eyeing new technologies. And despite challenges from the COVID-19 pandemic, analysts […]
COVID-19: Novel Treatment Protocols using Approved drugs vs Standard of Care vs Vaccine and Antiviral new drug discovery and development – An LPBI Group Response and An LPBI Group & Affiliates Response
Posted in Coronavirus Gene Expression, COVID-19, Population Health Management, Genetics & Pharmaceutical, SARS-CoV-2, Serology tests for coronavirus antibodies, Treatment Protocols for COVID-19, Vaccinology, Virus Infective Acute Respiratory Syndrome: SARS-CoV on May 29, 2020| Leave a Comment »
COVID-19: Novel Treatment Protocols using Approved drugs vs Standard of Care vs Vaccine and Antiviral new drug discovery and development – An LPBI Group Response and An LPBI Group & Affiliates Response Curator: Aviva Lev-Ari, PhD, RN On 5/26/2020 LPBI organized a Symposium on New Therapeutics for COVID-19 AGENDA included presentations by: Dr. Raphael […]
The Impact Of The Coronavirus Crisis On Mergers And Acquisitions
Posted in COVID-19, Economic Impact of Coronavirus Pandemic, Population Health Management on April 17, 2020| Leave a Comment »
The Impact Of The Coronavirus Crisis On Mergers And Acquisitions Reporter – Dr. Joel T. Shertok The Impact Of The Coronavirus Crisis On Mergers And Acquisitions By Richard D. Harroch, David A. Lipkin, and Richard V. Smith Forbes – April 17, 2020 The coronavirus (COVID-19) crisis is having and will continue to have a material global […]
Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus
Posted in on March 18, 2020|
Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus Aviva Lev-Ari, PhD, RN – March 14, 2020 to Present Lead Curator, e–mail Contact: AvivaLev-Ari@alum.berkeley.edu Therapeutical options for coronavirus viral infection include the following: (a) Monoclonal and polyclonal antibodies Therapeutic SARS-CoV neutralizing antibodies have been generated and could be retrieved and used again in the event of another […]
Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings
Posted in Drug Development Process, Intellectual Property, Pharmaceutical Analytics, Pharmaceutical Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, tagged #pharmanews, @Biotech News, Array Biopharma, Biotechnology in MA, BRAF, Colorectal cancer, M&A Brokers FINRA Guidance Investment Platforms for Private Placements Investment Platforms for Private Funds Crowdfunding, MEK inhibition, Mergers and acquisitions, Pfizer, pharma deals on June 17, 2019| Leave a Comment »
Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings Reporter: Stephen J. Williams, PhD As reported in FiercePharma.com: by Angus Liu | Jun 17, 2019 11:42am Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it’s betting on oncology. In the first […]
From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma
Posted in Cancer - General, Cancer and Current Therapeutics, Drug Development Process, Health Economics and Outcomes Research, Patents, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Uncategorized, tagged Bristol-Myers Squibb, Celgene, Drug Price Competition and Patent Term Restoration Act, health costs, Mergers and acquisitions, Multiple myeloma, Pfizer, pharma deals, Revlimid, thalidomide on January 25, 2019| Leave a Comment »
From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma Curator: Stephen J. Williams, Ph.D. Updated 6/24/2019 Updated 4/12/2019 Updated 2/28/2019 Lenalidomide (brand name Revlimid) is an approved chemotherapeutic used to treat multiple myeloma, mantle cell lymphoma, and certain myedysplastic syndromes. It is […]